251579-55-2

251579-55-2 structure

Name: ABT-510
Chemical Name: N-Acetyl-N-methylglycylglycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-N5-(diaminomethylene)-L-ornithyl-N-ethyl-L-prolinamide
CAS Number: 251579-55-2
Molecular Formula: C₄₆H₈₃N₁₃O₁₁
Molecular Weight: 994.23200
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2018-05-19 04:14:13
Modify Date: 2024-01-02 11:19:05
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD)[1][2].

Name	N-Acetyl-N-methylglycylglycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-N5-(diaminomethylene)-L-ornithyl-N-ethyl-L-prolinamide
Synonyms	L-Prolinamide, N-acetyl-N-methylglycylglycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-N-(diaminomethylene)-L-ornithyl-N-ethyl- N-Acetyl-N-methylglycylglycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-N-(diaminomethylene)-L-ornithyl-N-ethyl-L-prolinamide

Description	ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD)[1][2].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Research Areas >> Inflammation/Immunology
In Vitro	ABT-510 (1, 5, 10, 20, 50 nM; 24 h) induces apoptosis in ID8 cells and (50 nM; 24 h) increases the incidence of apoptosis in the human epithelial cancer cell lines SKOV3, OVCAR3, and CAOV3[1]. Apoptosis Analysis[1] Cell Line: ID8, SKOV3, OVCAR3, and CAOV3 cells Concentration: 1, 5, 10, 20, 50 nM Incubation Time: 24 h Result: Induced ID8 cells apoptosis and increased in apoptosis in the human EOC cell lines SKOV3, OVCAR3, and CAOV3.
In Vivo	ABT-510 (100 mg/kg; i.p.; single daily for 90 days) leads to a significant reduction in tumor size, ascites fluid volume, and secondary lesion dissemination in mice[1]. ABT-510 (100 mg/kg; I.p.; single daily for 90 days) induces cells apoptosis in vivo[1]. ABT-510 (60 mg/kg; osmotic minipumps for s.c.; single daily for 7 days) decreases angiogenesis and inflammation in a murine model of inflammatory bowel disease[2]. Animal Model: TSP-1-Null mice (C57BL/6 background; orthotopic, syngeneic model of epithelial ovarian cancer)[1]. Dosage: 100 mg/kg Administration: Intraperitoneal injection; single daily for 90 days Result: Reduced ovarian tumor growth in wild-type and TSP-1-Null Mice. Significantly reduced the volume of ascites and completely abolished the formation of peritoneal lesions. Reversed ovarian tumor hypervascularization and increased the proportion of mature blood vessels. Animal Model: TSP-1-Null mice (C57BL/6 background; 6-week-old; DSS-induced inflammatory bowel disease murine model)[2]. Dosage: 60 mg/kg Administration: Subcutaneously implanted osmotic minipumps (0.5µL/h); single daily for 7 days Result: Significantly delayed DSS-induced bleeding and improved the overall severity of disease.Significantly diminished inflammation grading and angiogenesis

Molecular Formula	C₄₆H₈₃N₁₃O₁₁
Molecular Weight	994.23200
Exact Mass	993.63400
PSA	358.05000
LogP	2.06520

251579-55-2	857447-92-8
1132940-31-8	161417-03-4
147388-83-8	450839-40-4
1132935-63-7	162829-90-5
1003021-91-7	1145655-58-8
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
6906-52-1	1394815-79-2
930439-75-1	1018584-77-4
1375289-11-4	849349-65-1